Short Interest in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Declines By 25.0%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 4,800 shares, a drop of 25.0% from the February 13th total of 6,400 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 8,600 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLGN. Renaissance Technologies LLC acquired a new stake in shares of CollPlant Biotechnologies during the 4th quarter valued at about $38,000. Wells Fargo & Company MN lifted its stake in CollPlant Biotechnologies by 110.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after acquiring an additional 4,405 shares during the last quarter. AMH Equity Ltd grew its position in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after acquiring an additional 17,295 shares in the last quarter. Finally, Benjamin Edwards Inc. acquired a new position in shares of CollPlant Biotechnologies during the 3rd quarter worth $112,000. Hedge funds and other institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

NASDAQ CLGN opened at $3.27 on Monday. CollPlant Biotechnologies has a 52-week low of $3.00 and a 52-week high of $6.75. The company has a 50 day simple moving average of $3.68 and a 200-day simple moving average of $4.08. The firm has a market capitalization of $37.43 million, a price-to-earnings ratio of -2.12 and a beta of 1.07.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a report on Friday, November 29th. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of CollPlant Biotechnologies in a research report on Wednesday, February 12th.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.